Neurodegenerative diseases early detection and monitoring system for point-of-care applications

被引:0
作者
Thakur, Rajiv [1 ,2 ]
Saini, Anil Kumar [2 ,3 ]
Taliyan, Rajeev [4 ]
Chaturvedi, Nidhi [1 ,2 ]
机构
[1] CSIR, Cent Elect Engn Res Inst, Semicond Sensors & Microsyst Grp, Pilani 333031, India
[2] Acad Sci & Innovat Res AcSIR, Ghaziabad 201002, India
[3] CSIR, Cent Elect Engn Res Inst, Integrated Circuits & Syst Grp, Pilani 333031, India
[4] Birla Inst Technol & Sci, Dept Pharm, Neuropsychopharmacol Div, Pilani 333031, Rajasthan, India
关键词
Neurodegenerative diseases; GaN HEMT biosensor; Early detection; Handheld system; Biomarkers; FIELD-EFFECT TRANSISTOR; BIOMARKERS; BIOSENSOR; ISFET;
D O I
10.1016/j.microc.2024.112280
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Millions of people worldwide are negatively impacted by a diverse range of brain conditions known as neurodegenerative diseases. The work reports a GaN HEMT-based biosensing system for the early detection and monitoring of neurodegenerative disease biomarkers in clinically relevant concentration ranges. The developed system offers a high sensitivity of 19.40 mu A/pg/ml, 0.52 mA/pg/ml, 0.69 mA/ng/ml, 0.13 mA/pg/ml, 23.66 mu A/ pg/ml, and 23.85 mu A/pg/ml for the detection of UCH-L1, GFAP, S100B, IL-6, A beta, and IFN-gamma respectively. The proposed biofunctionalization assay has an excellent specificity and selectivity, signal-to-noise ratio of 1:16, 1:23, and 1:38 for UCH-L1, GFAP, and S100B detection respectively with a LoD of 0.06 fg/ml. The platform has good repeatability with an average sensitivity of 19.41 mu A/pg/ml, 0.524 mA/pg/ml, and 0.704 mA/ng/ml for UCH-L1, GFAP, and S100B detection respectively. The sensors have a very good shelf-life for a storage time of 35 days with reductions of 1.39 %, 1.72 %, and 2.05 % in sensor response and 2.88 %, 2.76 %, and 2.96 % in sensitivity for UCH-L1, GFAP, and S100B respectively. The coefficient of variation (CV) values for conventional and meander-gated GaN HEMT biosensors were found to be similar to 0.038 and similar to 0.026 respectively. A slight variation of similar to 4.41 % in sensor response when the sensor was reused clearly demonstrates the sensor's reusability. A very high resolution with detection capability in the ultra-low concentration of fg/ml with good linearity and quantifiable sensor response which is a key requirement for early-stage detection of diseases has been observed for sensor design with source-to-drain distance (L-sd) of 10 mu m. Thus, the platform capability and suitability for early detection and prognosis of neurodegenerative disease detection and monitoring have been demonstrated. Further, the system can be imperative in patient screening in clinical, sports, and warfare for CT or MRI scan requirements.
引用
收藏
页数:12
相关论文
共 77 条
  • [1] Aarsland D, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00280-3
  • [2] Emerging Biosensing Technologies for Neuroinflammatory and Neurodegenerative Disease Diagnostics
    Abreu, Catarina M.
    Soares-dos-Reis, Ricardo
    Melo, Pedro N.
    Relvas, Joao B.
    Guimaraes, Joana
    Sa, Maria Jose
    Cruz, Andrea P.
    Pinto, Ines Mendes
    [J]. FRONTIERS IN MOLECULAR NEUROSCIENCE, 2018, 11
  • [3] Alz, What is Alzheimer's Disease? Symptoms & Causes
  • [4] 2021 Alzheimer's disease facts and figures
    不详
    [J]. ALZHEIMERS & DEMENTIA, 2021, 17 (03) : 327 - 406
  • [5] Dementia in the UK: preparing the NHS for new treatments
    不详
    [J]. LANCET, 2018, 391 (10127) : 1237 - 1237
  • [6] [Anonymous], Guidance document on the estimation of LOD and LOQ for measurements in the field of contaminants in feed and food-Publications Office of the EU
  • [7] [Anonymous], Study of interleukin-6 production in Alzheimer's disease
  • [8] [Anonymous], ALZHEIMERS FACTS FIG
  • [9] [Anonymous], Dementia statistics
  • [10] [Anonymous], Parkinson's disease: Challenges, progress, and promise